Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 2806 AL 2820

The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease

Kikis EA.

Biol Direct. 2016 Nov 3;11(1):58. doi: 10.1186/s13062-016-0161-2.

AMPK in Neurodegenerative Diseases

Domise M, Vingtdeux V.

Exp Suppl. 2016;107:153-177. doi: 10.1007/978-3-319-43589-3_7.

Dopamine depleters in the treatment of hyperkinetic movement disorders

Jankovic J.

Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. doi: 10.1080/14656566.2016.1258063.

Movement Disorders Associated With Hemochromatosis

Kumar N, Rizek P, Sadikovic B, Adams PC, Jog M.

Can J Neurol Sci. 2016 Nov;43(6):801-808. doi: 10.1017/cjn.2016.286.

A rare case of movement disorder in Intensive Care Unit

Sikri V, Jain A, Singhal V, Gupta A.

Indian J Crit Care Med. 2016 Oct;20(10):605-607. doi: 10.4103/0972-5229.192055.

A novel ANO3 variant identified in a 53-year-old woman presenting with hyperkinetic dysarthria, blepharospasm, hyperkinesias, and complex motor tics

Blackburn PR, Zimmermann MT, Gass JM, Harris KG, Cousin MA, Boczek NJ, Ross OA, Klee EW, Brazis PW, Van Gerpen JA, Atwal PS.

BMC Med Genet. 2016 Dec 5;17(1):93. doi: 10.1186/s12881-016-0354-7.

A common PRRT2 mutation in familial paroxysmal kinesigenic dyskinesia in Hong Kong: a case series of 16 patients

Law CY, Yeung WL, Cheung YF, Chan HF, Fung E, Hui J, Yung IO, Yuen YP, Chan AO, Lam CW.

Hong Kong Med J. 2016 Dec;22(6):619-22. doi: 10.12809/hkmj154579.

Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review

Wen MM.

Front Mol Neurosci. 2016 Nov 22;9:129. doi: 10.3389/fnmol.2016.00129. eCollection 2016.

Examination of Huntington's disease with atypical clinical features in a Bangladeshi family tree

Al-Mamun MM, Sarker SK, Qadri SK, Shirin T, Mohammad QD, LaRocque R, Karlsson EK, Saha N, Asaduzzaman M, Qadri F, Mannoor MK.

Clin Case Rep. 2016 Nov 11;4(12):1191-1194. doi: 10.1002/ccr3.743. eCollection 2016 Dec.

Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD

Downing NR, Lourens S, De Soriano I, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

J Huntingtons Dis. 2016 Dec 15;5(4):357-368. doi: 10.3233/JHD-160185.

Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease

D'Souza GX, Waldvogel HJ.

J Huntingtons Dis. 2016 Dec 15;5(4):333-342. doi: 10.3233/JHD-160200.

Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation

Rangel-Barajas C, Rebec GV.

J Huntingtons Dis. 2016 Dec 15;5(4):303-331. doi: 10.3233/JHD-160221.

Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases

Preciados M, Yoo C, Roy D.

Int J Mol Sci. 2016 Dec 13;17(12):2086. doi: 10.3390/ijms17122086.

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Coisne C, Tilloy S, Monflier E, Wils D, Fenart L, Gosselet F.

Molecules. 2016 Dec 20;21(12):1748. doi: 10.3390/molecules21121748.

Time Processing and Motor Control in Movement Disorders

Avanzino L, Pelosin E, Vicario CM, Lagravinese G, Abbruzzese G, Martino D.

Front Hum Neurosci. 2016 Dec 12;10:631. doi: 10.3389/fnhum.2016.00631. eCollection 2016.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias